As drugs are being developed for other GTPases [54], ARF1 or Cdc42 are potentially suitable targets for therapeutic development for JNCL, a currently untreatable, fatal neurodegenerative disease. This evidence concerns the gene ARF1 and juvenile neuronal ceroid lipofuscinosis.